Utilize a Computational Predictive Biology (CPB) platform to discover and develop life-science products. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 43% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 1.1× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 26% of them.
Analysts' average target sits 348% above today's price.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $3.9M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 2 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $8.5M against $3.9M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.48. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
On our five-subject report card, EVGN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EVGN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (26/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.